We distribute our research widely to institutional and retail investors through various channels, including our proprietary database, website, and other platforms (such as Bloomberg, Thomson Reuters and Factset).

We are fully MiFID II compliant. Our research is paid for by our corporate clients, and we do not carry out any execution business.

Published reports can be obtained by searching our Research Library below, or directly from the relevant Company Pages.

Advanced search
Date range (dd-mm-yyyy)

Redx Pharma

New data draws attention to promising fibrosis assets

Update | 07 October 2022

ANGLE

Post-FDA approval commercial momentum is building

Lighthouse | 29 September 2022

Allergy Therapeutics

On the starting blocks towards key data expected in 2023

Update | 29 September 2022

MaxCyte

Vertex Pharmaceuticals secures exa-cel SPL

Lighthouse | 29 September 2022

Avacta

Building Tx and Dx portfolios from proprietary platforms

Lighthouse | 29 September 2022

HUTCHMED

FRESCO-2 data support broad uptake in later-line mCRC

Update | 21 September 2022

Arecor Therapeutics

Broadening opportunities and preparing for the future

Update | 21 September 2022

Futura Medical

Interims highlight positive first signs in key markets

Lighthouse | 13 September 2022

Arecor Therapeutics

Key clinical diabetes events on track for H222

Lighthouse | 08 September 2022

HUTCHMED

Rich and diverse pipeline with multiple waves of growth

Update | 06 September 2022
< 3 4 5 6 7 8 9 10 11 12 >
397 results found.